MESO FY 2013 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M-24.8% YoY

Gross Profit

$8M26.1% margin

Operating Income

-$60M-208.7% margin

Net Income

-$62M-214.2% margin

EPS (Diluted)

$-1.10

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$57M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$884M

Total Liabilities

$253M

Stockholders' Equity

$630M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$38M	-24.8%
Gross Profit	$8M	$38M	-80.4%
Operating Income	-$60M	-$49M	-23.3%
Net Income	-$62M	-$71M	+13.3%